Dashboard
Manage Tickers

APVO Aptevo Therapeutics Inc.

Nasdaq aptevotherapeutics.com


$ 1.47 $ -0.02 (-1.34 %)    

Wednesday, 12-Nov-2025 13:23:44 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 620.91 $ -3.87 (-0.62 %)
DIA $ 483.22 $ 2.63 (0.55 %)
SPY $ 683.59 $ -1.20 (-0.18 %)
TLT $ 90.13 $ 0.18 (0.2 %)
GLD $ 386.94 $ 6.79 (1.79 %)
$ 1.5
$ 1.48
$ 1.47 x 650
$ 1.48 x 200
$ 1.46 - $ 1.51
$ 1.32 - $ 298.00
486,521
na
25.28M
$ 0.89
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-11-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 02-14-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 03-05-2024 12-31-2023 10-K
9 11-14-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-30-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-24-2022 12-31-2021 10-K
17 11-12-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
19 05-11-2021 03-31-2021 10-Q
20 03-31-2021 12-31-2020 10-K
21 11-10-2020 09-30-2020 10-Q
22 08-14-2020 06-30-2020 10-Q
23 05-13-2020 03-31-2020 10-Q
24 03-25-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-09-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 03-18-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-13-2018 12-31-2017 10-K
33 11-13-2017 09-30-2017 10-Q
34 08-10-2017 06-30-2017 10-Q
35 05-12-2017 03-31-2017 10-Q
36 03-31-2017 12-31-2016 10-K
37 11-14-2016 09-30-2016 10-Q
38 08-25-2016 06-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

aptevo-highlights-nov-8-presentation-of-apvo451-data-at-society-for-immunotherapy-of-cancer-sitc-annual-meeting
Aptevo Highlights Nov. 8 Presentation Of A...
11/10/2025 13:13:18

aptevo-therapeutics-q3-eps-223-misses-209-estimate
Aptevo Therapeutics Q3 EPS $(2.23) Misses ...
11/06/2025 13:37:28

Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(2.23) per share which missed the analyst consensus estimate of...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/07/2025 17:06:17

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/07/2025 12:08:21

why-telomir-pharmaceuticals-shares-are-trading-higher-by-31-here-are-20-stocks-moving-premarket
Why Telomir Pharmaceuticals Shares Are Tra...
10/07/2025 09:28:45

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
10/06/2025 21:06:27

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
09/19/2025 17:06:19

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
09/19/2025 12:09:04

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/18/2025 17:06:02

gold-falls-over-1-darden-posts-downbeat-earnings
Gold Falls Over 1%; Darden Posts Downbeat ...
09/18/2025 16:27:56

nasdaq-surges-100-points-bionano-genomics-shares-plunge
Nasdaq Surges 100 Points; Bionano Genomics...
09/18/2025 13:59:31

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/18/2025 12:09:24

Core News & Articles
Market-Moving News for September 18th
09/18/2025 11:21:57

INTC: 34% | Nvidia And Intel To Jointly Develop AI Infrastructure And Personal Computing Products, Nvidia To Invest $5B In Inte...

why-bullish-shares-are-trading-higher-by-12-here-are-20-stocks-moving-premarket
Why Bullish Shares Are Trading Higher By 1...
09/18/2025 09:09:13

aptevo-therapeutics-surges-over-46-after-hours-on-breakthrough-aml-treatment-results
Aptevo Therapeutics Surges Over 46% After ...
09/18/2025 07:58:19

APVO shares rose 46.10% to $2.06 after promising clinical results, but the stock has dropped 98.84% over the past year.

steven-cohen-reports-91-passive-stake-in-aptevo-therapeutics--as-of-september-16
Steven Cohen Reports 9.1% Passive Stake In...
09/17/2025 21:37:21

-SEC Filing

aptevos-mipletamig-achieves-100-remission-with-favorable-safety-in-phase-1b2-aml-trial-cohort-4-now-open-for-enrollment
Aptevo's Mipletamig Achieves 100% Remissio...
09/16/2025 12:33:16

No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable s...

aptevo-expands-anti-cancer-pipeline-with-patents-for-apvo452-apvo451-acute-myeloid-leukemia-candidate-mipletamig-shows-strong-clinical-validation
Aptevo Expands Anti-Cancer Pipeline With P...
09/04/2025 12:50:14

New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor canc...

aptevo-unveils-apvo442-precision-cd3-bispecific-for-prostate-cancer-advancing-solid-tumor-strategy-with-cris-7-platform
Aptevo Unveils APVO442 Precision CD3 Bispe...
08/13/2025 12:14:38

Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for preci...

aptevo-therapeutics-q2-eps-840-beats-8320-estimate
Aptevo Therapeutics Q2 EPS $(8.40) Beats $...
08/11/2025 12:10:57

Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(8.40) per share which beat the analyst consensus estimate of $...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION